Exact Therapeutics Valuation
| EXTX Stock | NOK 5.70 0.10 1.72% |
At this time, the firm appears to be overvalued. Exact Therapeutics shows a prevailing Real Value of 4.58 per share. The current price of the firm is 5.7. Our model computes the value of Exact Therapeutics from reviewing the firm fundamentals such as Operating Margin of (844.98) %, shares outstanding of 30 M, and Current Valuation of 432.68 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Exact Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Exact Therapeutics is based on 3 months time horizon. Increasing Exact Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Exact stock is determined by what a typical buyer is willing to pay for full or partial control of Exact Therapeutics AS. Since Exact Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Exact Stock. However, Exact Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.7 | Real 4.58 | Hype 5.7 |
The intrinsic value of Exact Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Exact Therapeutics' stock price.
Estimating the potential upside or downside of Exact Therapeutics AS helps investors to forecast how Exact stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Exact Therapeutics more accurately as focusing exclusively on Exact Therapeutics' fundamentals will not take into account other important factors: Exact Therapeutics Total Value Analysis
Exact Therapeutics AS is currently expected to have takeover price of 432.68 M with market capitalization of 359.97 M, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Exact Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
432.68 M | 359.97 M |
Exact Therapeutics Asset Utilization
One of the ways to look at asset utilization of Exact is to check how much profit was generated for every dollar of assets it reports. Exact Therapeutics AS shows a negative utilization of assets of -0.26 percent, losing 0.00256 for each kroner of assets held by the firm. Unsuccessful asset utilization denotes the company is being less effective with each kroner of assets it shows. Put another way, asset utilization of Exact Therapeutics AS shows how unproductive it operates for each kroner spent on its assets.Exact Therapeutics Ownership Allocation
Exact Therapeutics holds a total of 30 Million outstanding shares. Exact Therapeutics AS shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.13 percent of Exact Therapeutics outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Exact Therapeutics Profitability Analysis
Net Loss for the year was (58.59 M) with profit before overhead, payroll, taxes, and interest of 52 K.About Exact Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Exact Therapeutics AS. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Exact Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Exact Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Exact Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Exact Therapeutics. We calculate exposure to Exact Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Exact Therapeutics's related companies.EXACT Therapeutics AS, a clinical stage biotech company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy . The company was founded in 2012 and is based in Oslo, Norway. EXACT THERAPEUTICS is traded on Oslo Stock Exchange in Norway.
8 Steps to conduct Exact Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Exact Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Exact Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Exact Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Exact Therapeutics' revenue streams: Identify Exact Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Exact Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Exact Therapeutics' growth potential: Evaluate Exact Therapeutics' management, business model, and growth potential.
- Determine Exact Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Exact Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Other Information on Investing in Exact Stock
Exact Therapeutics financial ratios help investors to determine whether Exact Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Exact with respect to the benefits of owning Exact Therapeutics security.